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Objective: Ultrasonography (US) demonstrated to be a promising tool for the diagnosis of calcium py-
rophosphate dihydrate deposition disease (CPPD). The aim of this systematic literature review (SLR) was
to collect the definitions for the US elementary lesions and to summarize the available data about US
diagnostic accuracy in CPPD.
Methods: We systematically reviewed all the studies that considered US as the index test for CPPD
diagnosis without restrictions about the reference test or that provided definitions about US identifi-
cation of CPPD. Sensitivity and specificity were calculated for each study and definitions were extrap-
olated. Subgroup analyses were planned by anatomical site included in the index text and different
reference standards.
Results: Thirty-seven studies were included in this review. All the studies were eligible for the collection
of US findings and all definitions were summarized. US description of elementary lesions appeared
heterogeneous among the studies. Regarding US accuracy, 13 articles entered in the meta-analysis.
Considering each joint structure, the sensitivity ranged between 0.77 (0.63e0.87) and 0.34 (0.16e0.58)
while the specificity varies between 1.00 (0.89e1.00) and 0.92 (0.16e1.00). Considering the reference
standards used, the sensibility ranged between 0.34 (0.02e0.65) and 0.87 (0.76e0.99) while specificity
ranged between 0.84 (0.52e1.00) and 1.00 (0.99e1.00).
Conclusion: US is potentially a useful tool for the diagnosis of CPPD but universally accepted definitions
and further testing are necessary in order to assess the role of the technique in the diagnostic process.
© 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Calcium pyrophosphate dihydrate deposition disease (CPPD) is
the third most common inflammatory arthritis1 and its preva-
lence grows with ageing2. For many years, the diagnosis of CPPD
has been based on the McCarty criteria3, which includes the
presence of typical crystal deposits at conventional radiology (CR): G. Filippou, Department of
Section, Policlinico le Scotte,
70/1; Fax: 39-0577-40450.
).
ternational. Published by Elsevier Land synovial fluid analysis. In the last decade, ultrasonography
(US) has been extensively used for detecting calcium pyrophos-
phate dihydrate crystal (CPP) deposits in joint and periarticular
tissues, demonstrating to be a useful diagnostic tool for this
condition4e11.
Recently, a task force of the European League Against Rheu-
matism (EULAR)12 has published a set of recommendations for
CPPD regarding terminology, diagnosis and management. The ex-
perts, after a systematic review of the literature, concluded that US
can demonstrate CPP crystals in peripheral joints with high accu-
racy. This is the first time that US enters, although only as recom-
mendation, in a diagnostic criteria set for CPPD.td. All rights reserved.
Fig. 1. Phases of the study selection (PRISMA flow-chart).
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981974Because of the increasing interest in the role of US as diagnostic
tool for CPPD, it seemed timely to summarize the results of the
available literature. To the best of our knowledge, a US protocol for
the identification of CPPD deposits is not currently available and
there is a great heterogeneity in the literature in terms of inclusion
criteria, study design, and type of reference standard.
The objective of this study was double: the evaluation of US
diagnostic accuracy in the diagnosis of CPPD and the collection of
the definitions available in the literature about US elementary
findings detectable in CPPD in order to define the US specific le-
sions for this disease. To achieve our aims, we performed a sys-
tematic literature review (SLR) and subsequent meta-analyses in
which we considered US as index test and other diagnostic tools as
reference standards for the diagnosis of CPPD.
Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines for reporting systematic re-
views and meta-analysis were used for this review13. Before
beginning the study, a protocol that defined all the aspects of each
phase (research questions, search strategy, inclusion criteria for the
articles and methods for the analysis) was developed.
Structured search strategy
The research was performed by one author and the control
search by another one. We used the Medline (Pubmed), Embase,
Dare and Cochrane databases, starting our research from January 1,
1980. The search strategies are shown in the Supplemental Fig. 1
and were based on terms related to CPPD and US. No language or
publication restrictions were applied and studies were not selected
on the basis of their quality.
Study selection and data extraction
The final selection included studies on patients with suspected
CPPD, independently of the clinical subtype, in which US was
considered the index test, without restrictions about the reference
test. No limitations were applied regarding the study type: pro-
spective and retrospective diagnostic cohort studies, case control
studies, case reports and reviews were eligible for inclusion in the
review. For the eligibility of each study, we required the presence of
sufficient data to build a 22 table of diagnostic performance and/
or the presence of the definitions of US elementary lesions of CPPD
in order to satisfy one of our end points or both of them.
Two authors independently screened the titles and the abstracts
of the papers. An inclusion assessment was performed on the full-
text of the potentially eligible articles by one reviewer and checked
by a second. Discordant assessments between authors were
resolved by consensus.
Datawere extracted using a standardized form including author,
publication year, index test, target condition, study design, inclu-
sion criteria, number of patients, setting (inpatients, outpatients),
reference standards, and 22 tables for every couple of index and
reference test. The data about accuracy were extracted as 22 ta-
bles. The definitions of the US elementary lesions were summarized
in ad hoc tables.
Quality assessment
The quality of selected studies was assessed using the modified
version of the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) tool14. Data extraction and quality assessment were
performed by one reviewer and checked by a second one.Data analysis
Sensitivity and specificity were calculated for each 22 set of
data. Heterogeneity among included studies was visually evaluated,
by plotting sensitivity and specificity on a receiver operating
characteristic (ROC) graph, and separately tested by the Chi-square
test using n  1 degrees of freedom.
In the presence of heterogeneity and negative correlation be-
tween sensitivity and specificity, as commonly seen in diagnostic
studies, the bivariate model was used to estimate summary sensi-
tivity and specificity with 95% confidence intervals (CI) and to
derive a hierarchical summary receiv operat characteristic (HSROC)
curve15.
Given the expected methodological heterogeneity, subgroup
analyses by anatomical sites examined by the index text were
planned. The influence of different reference standards has been
explored by univariable meta-regression analyses. Publication bias
was indirectly assessed by the funnel plot of logDOR. Formal testing
of asymmetry was calculated. Influential observations and outliers
were evaluated by plotting Cook's distance and standardized pre-
dicted random effects (standardized level-2 residuals), respectively.
Stata, version 11 (StataCorp, College Station, Texas) was used to
perform all analyses. In particular the generalized linear mixed
model approach to bivariate meta-analysis of sensitivity and
specificity was obtained using the ‘metandi’ and ‘midas’ commands
of Stata.Results
Description of the studies
The search strategy identified 238 articles. Fig. 1 reports the
phases of the selection process. After the first evaluation of the ti-
tles and abstracts, 41 full-text articles were included for the review
but four articles16e19 were rejected afterwards. The rejection of two
of these studies16,17 was due to a lack of sufficient data to satisfy at
least one of our objectives, while two other articles18,19 were
rejected because the US was used as reference test.
Of the remaining 37 articles4e11,20e48, 10 were case control
studies4e8,10,30,31,41,43, 12 were cohort studies9,11,21,22,24,32e36,38,44,
eight were case reports20,23,26,27,40,46e48, and seven
reviews25,28,29,37,39,42,45.
Considering the cohort studies, the mean number of patients
included was 46 (SD ± 28, range 6e100) and the median value was
42. The mean age of subjects enrolled was 66 years (SD ± 9.37,
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available information a higher prevalence of males was present
(approximately 58%).
In the caseecontrol studies, the mean number of patients
enrolled as cases was 37.7 (SD ± 25, range 11e80) and the median
value was 33. The mean age of these patients was 61 years (SD ± 16,
range 49e69). Regarding the control groups, the mean number of
patients included was 40 (SD ± 30, 13e100) and the median value
was 25. The mean age was 61 years (SD ± 8.47, range 45e69).
Although the exact sex ratio is not reported in all studies, there is a
weak prevalence of males among cases (51%) and a higher preva-
lence of females among controls (63%). Furthermore, in most
studies, controls are affected by other rheumatic diseases such as
osteoarthritis (OA), rheumatoid arthritis (RA) or psoriatic arthritis
(PsA), and gout. Only in two studies, the controls were healthy
subjects.
Regarding the reference standard used, the diagnosis of CPPD
was based on the McCarty criteria in six studies6,10,11,30,36,38, on a
positive synovial fluid analysis in 107,9,21,22,31,32,41,43,44, and on the
presence of radiographic chondrocalcinosis (CC) in two4,5. In three
studies, produced by the same group, the reference standard was
the microscopic analysis of the specimens33e35.
Descriptive data of the studies are summarized in Table I.Diagnostic accuracy results
Regarding the evaluation of US diagnostic accuracy in CPPD,
only 13 studies had enough data for constructing the contingency
tables but in one of these4e6,8,10,22,30,31,34,35,41,43, only sensitivity
could be calculated21.
In all the selected studies but five8,22,31,35,43 the data were
suitable for defining US sensitivity and specificity only at the level
of a single joint structure (i.e., cartilage, fibrocartilage, tendon) and
not at the level of the whole joint or patient.
The values of sensitivity and specificity for each study are
illustrated in Table II while Fig. 2 illustrates the ROC curves about
the sensitivity and specificity values relating at a single structure
and at joint/patient level.
For the studies considering the whole patient and not a single
structure8,22,31,35,43, sensitivity and specificity ranged from 0.60 to
1.00 and from 0.88 to 1, respectively. The pooled sensitivity was
0.89 (95% CI 0.72e0.97) and specificity was 0.94 (95% CI 0.87e0.98).
Considering the US performance at the level of each joint
structure, the highest value of sensitivity was obtained at the hy-
aline cartilage4,5,10,21,35,41,43 with a pooled sensitivity of 0.77 (95% CI
0.63e0.87) and specificity of 0.92 (0.16e1.00), and at the fibro-
cartilage4,34,35,41,43 with a pooled sensitivity of 0.77 (95% CI
0.31e0.96) and specificity of 0.96 (95% CI 0.75e1.00), while for the
tendons6,30 the sensitivity and specificity were respectively 0.34
(0.16e0.58) and 1.00 (95% CI 0.89e1.00).
Another important source of heterogeneity among the studies
was the type of reference standard used. Considering synovial fluid
analysis8,21,22,31,41,43 as reference standard, the pooled sensitivity of
US was 0.87 (95% CI 0.76e0.99) and specificity 0.98 (0.96e1.00).
When the reference standard was radiography4,5 the sensitivity of
US was 0.58 (95% CI 0.09e1.00) and specificity 0.84 (95% CI
0.52e1.00). In comparison to McCarty criteria6,10,30, US sensitivity
and specificity were 0.34 (95% CI 0.02e0.65) and 1.00 (95% CI
0.99e1.00), respectively. Finally using microscopic analysis as
reference standard34,35, sensitivity was 0.84 (95% CI 0.61e1.00) and
specificity 0.93 (0.77e1.00). The lowest values of sensitivity have
been calculated in the studies that evaluated tendons for the
presence of CPPD and for those that adopted the McCarty criteria as
the reference standard.Methodological quality assessment
Most of the studies had a low risk of bias in many items. How-
ever two of them6,10 had a high risk of differential verification bias
because some of the index test results were verified by different
reference standards.
Regarding the time of execution of index and reference tests, in
most of the studies the delay between them was not reported. In
one study the risk of bias was low (the delay between tests was less
than an hour)8 and in another one41 it was high because of the use
of an historical archive of synovial fluid analyses to select the
controls. Furthermore, in some studies the blinding of the index
and reference tests was not explicitly reported4e6,10,21,22,30,31,41,43.
Finally, most of the studies were transversal and no withdrawals of
patients were reported in any study. The evaluation of the meth-
odological quality of the included studies is represented in Fig. 3.
Two studies5,6 resulted both outliers and influential. Excluding
those influential observations, the overall sensitivity changes from
0.75 (95% CI) to 0.79 (0.64e0.89) and specificity from 0.98
(0.92e0.99) to 0.97 (0.95e0.99).
Finally, publication bias was indirectly evaluating the symmetry
on the funnel plot of logDOR. This diagram and forma testing
showed a marginally significant small study effect, but not in the
direction of publication bias (Supplemental Fig. 2).
Definition of US specific findings in CPPD
Considering the second end point of this systematic review,
almost all studies were eligible. The definitions used for the iden-
tification of the US features of CPP deposits were divided depending
on the anatomical structure under examination. In particular,
different definitions were used for CPP deposition at the level of
hyaline cartilage, fibrocartilage, tendons and synovial fluid.
Considering the hyaline cartilage, CPP crystals are generally
described as hyperechoic deposits, placed within the layer of the
cartilage, that reach large dimensions. At the level of the fibro-
cartilage, CPP crystals usually appear as hyperechoic, rounded or
amorphous-shaped deposits placed within the structure. In the
tendons, CPP crystals are usually described as linear deposits
within the fibrillar echotexture (multiple or single lines or thick
solid band), but in some studies these deposits are described also as
punctate. Finally, in the synovial fluid CPP crystals appear as
hyperechoic spots or ovalar aggregates. The definitions used in the
studies for US diagnosis of CPPD were summarized in Table III and
characteristic examples of CPPD appearance in US are provided in
Fig. 4.
Discussion
For many years, the diagnosis of CPPD has been based on the
McCarty criteria3 that were based on CR and synovial fluid analysis.
In the last years US has demonstrated to be a potential alternative
diagnostic method7,8,10 and has been included in the diagnostic
methods proposed by the EULAR task force for diagnosis of the
disease12. To the best of our knowledge, this is the first systematic
review on the diagnostic accuracy of US in CPPD and global results
confirm a good diagnostic accuracy of US, however some issues can
been raised regarding mainly different methodology between
studies.
Of the 37 studies included in the review, 21 came from two
centres: Siena (eight papers) and Jesi (13 papers) in Italy. Generally,
25 out of 37 studies have been carried out in Italy, denoting a
particular interest for this disease. Excluding the case reports (eight
papers) and the review articles (seven papers), 22 studies investi-
gated the utility of US in CPPD. Twelve articles tried to assess the
Table I
Characteristics of the included studies. N number of patients included; n.a not applicable; US ultrasound; SFA synovial fluid analysis, XR radiography; MAmicroscopic analysis;
ARA American Rheumatism Association
Author Study design Inclusion criteria N Index test Reference tests
1995 Coari4 Case control Two groups of subjects. In the first, the patients were affected by
CPPD defined according to McCarty criteria. The controls were
healthy subjects.
28 Cases 46 controls US XR
2000 Monteforte46 Case report n.a n.a n.a n.a
2002 Farina32 Cohort study Consecutive patients affected by several rheumatic diseases (RA,
PsA, gout, CPPD, post-traumatic synovitis, septic arthritis, OA).
69 US SFA
2002 Foldes5 Case control Two groups of patients. In the first, the patients had a history of
unilateral knee CC. In the second, the patients were affected by mild
OA without CC at XR.
21 Cases 19 controls US XR
2002 Sofka48 Case report n.a n.a n.a n.a
2004 Falsetti6 Case control Two groups of subjects. In the first, the patients were affected by
CPPD defined according to McCarty criteria. In the second, 50
controls were affected by knee OA without signs of CC at XR and 50
controls were healthy subjects.
57 Cases 100 controls US SFA þ XR
2005 Frediani7 Case control Two groups of subjects. In the first, the patients with US features of
CPPD. In the second, patients without US signs of CPPD.
11 Cases 13 controls US SFA
2006 Grassi9 Cohort study Consecutive patients affected by crystal-related arthropathies (34
with CPPD and 26 with gout) confirmed by SFA.
60 US SFA
2007 Delle Sedie28 Review n.a n.a n.a n.a
2007 Filippou8 Case control Two groups of patients. In the first, patients with knee effusion and
US features of CPPD. In the second, the patients had knee effusion
without US signs of CPPD.
14 Cases 29 controls US SFA
2008 Ciapetti24 Cohort study Presence of CPP crystals confirmed by analysis of synovial fluid. 42 US SFA
2009 Filippucci10 Case control Two groups of subjects. In the first, 48 patients were affected by
CPPD according to McCarty criteria and 32 affected by gout
according to ARA guidelines In the second, the controls were
patients affected by RA, PsA or OA.
80 Cases 52 controls US SFA þ XR
2009 Gutierrez42 Review n.a n.a n.a n.a
2010 Filippucci11 Cohort study Two cohorts of subjects. In the first, the patients were affected by
CPPD according to McCarty criteria. In the second, the patients were
affected by gout, diagnosed using ARA guidelines.
70 CPPD 30 gout US SFA þ XR
2010 Dufauret-Lombard29 Review n.a n.a n.a n.a
2010 Gutierrez40 Case report n.a n.a n.a n.a
2011 Checa23 Case report n.a. 1 n.a n.a
2011 Di Geso27 Case report n.a n.a n.a n.a
2012 Di Geso26 Case report n.a n.a n.a n.a
2012 Ellabban30 Case control Two groups of subjects. In the first, the patients were affected by
CPPD defined according to McCarty criteria. In the second the
patients were affected by OA without CPP crystals at SFA or signs of
CC at XR.
38 Cases 22 controls US SFA þ XR
2012 Filippou34 Cohort study Consecutive patients who waiting to undergo knee replacement
surgery.
6 US MA
2012 Ellabban31 Case control A cohort of patients with knee effusion was divided in two groups.
In the first, the patients were positive for CPP crystals according to
SFA. In the second, the patients were negative for CPP crystals at
SFA.
60 US SFA
2012 Filippucci37 Review n.a n.a n.a n.a
2012 Magarelli45 Review n.a n.a n.a n.a
2013 Adinolfi20 Case report n.a. 1 n.a n.a
2013 Barskova21 Cohort study Patients < 60 years with diagnosis of CPPD defined according to
McCarty criteria.
25 US SFA
2013 Catay22 Cohort study Consecutive patients > 50 years with knee effusion on clinical
examination.
39 US SFA
2013 Filippou33 Cohort study Consecutive patients who waiting to undergo knee replacement
surgery.
6 US MA
2013 Dejaco25 Review n.a n.a n.a n.a
2013 Filippou36 Cohort study Patients affected by CPPD defined according to McCarty criteria. 42 US SFA þ XR
2013 Filippucci38 Cohort study Two cohorts of subjects. In the first, the patients were affected by
CPPD defined according to McCarty criteria. In the second, the
patients were affected by gout, diagnosed using ARA guidelines.
42 Gout 46 CPPD US SFA þ XR
2013 Kudaeva44 Cohort study Patients affected by crystal-related arthropathies (gout or CPPD)
confirmed by synovial fluid analysis.
15 US SFA
2013 Russell47 Case report n.a n.a n.a n.a
2014 Gutierrez41 Case control Two groups of subjects. In the first, the patients were affected by
CPPD defined according to SFA. In the second, the patients were
affected by AR, seronegative arthritis, gout and OA and not having
CPP crystals at synovial fluid analysis.
74 Cases 83 controls US SFA
2014 Filippou35 Cohort study Consecutive patients waiting to undergo knee replacement surgery. 42 US MA
2014 Filippucci39 Review n.a n.a n.a n.a
2014 Juge43 Case control Patients with painful knee effusion. The final diagnosis of CPPD was
proven by identification of CPP crystals in SFA.
n.a US SFA
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981976
Table II
Values of sensitivity and specificity of each study included. SFA synovial fluid analysis, XR radiography; MA microscopic analysis
Study Structure assessed Reference standard Sensitivity (95% CI) Specificity (95% CI)
Coari 19954 Hyaline cartilage XR 0.80 (0.66e0.90) 0.00 (0.00e0.46)
Coari 19954 Fibrocartilage XR 0.07 (0.02e0.20) 1.00 (0.78e1.00)
Foldes 20025 Hyaline cartilage XR 0.89 (0.74e0.97) 0.91 (0.78e0.97)
Falsetti 20046 Achilles tendon McCarty criteria 0.58 (0.44e0.71) 1.00 (0.96e1.00)
Falsetti 20046 Plantar fascia McCarty criteria 0.16 (0.07e0.28) 0.99 (0.95e1.00)
Filippou 20078 Any SFA 0.87 (0.60e0.98) 0.97 (0.83e1.00)
Filippucci 200910 Hyaline cartilage SFA 0.69 (0.54e0.81) 0.98 (0.92e1.00)
Ellaban 201230 Achilles tendon McCarty criteria 0.58 (0.41e0.74) 1.00 (0.85e1.00)
Ellaban 201230 Plantar fascia McCarty criteria 0.16 (0.06e0.31) 1.00 (0.85e1.00)
Ellaban 201231 Any SFA 0.84 (0.69e0.94) 1.00 (0.79e1.00)
Barskova 201321 Hyaline cartilage SFA 1.00 (0.86e1.00)
Filippou 201234 Fibrocartilage MA 0.56 (0.21e0.86) 0.50 (0.01e0.99)
Catay 201322 Any SFA 0.60 (0.32e0.84) 0.97 (0.88e1.00)
Gutierrex 201441 Hyaline cartilage SFA 0.59 (0.47e0.71) 1.00 (0.95e1.00)
Gutierrez 201441 Fibrocartilage SFA 0.91 (0.81e0.96) 1.00 (0.95e1.00)
Filippou 201435 Any MA 0.96 (0.80e1.00) 0.88 (0.62e0.98)
Filippou 201435 Hyaline cartilage MA 0.50 (0.19e0.81) 1.00(0.74e1.00)
Filippou 201435 Fibrocartilage MA 0.96 (0.80e1.00) 0.88 (0.62e0.98)
Juge 201443 Any SFA 1.00 (0.79e1.00) 0.88 (0.62e0.98)
Juge 201443 Fibrocartilage SFA 0.94 (0.70e1.00) 0.88 (0.62e0.98)
Juge 201443 Hyaline cartilage SFA 0.75 (0.48e0.93) 0.94 (0.70e1.00)
Fig. 2. ROC curves about the sensitivity and specificity values relating any structures or a single one.
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981 977
Fig. 3. Evaluation of the methodological quality of the included studies.
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981978ultrasonographic appearance of CPP deposition and 10 of them
assessed the sensitivity and specificity of US in CPPD. As described
in the results however, not all the studies evaluated the diagnostic
accuracy of US at the patient level. Most of them assessed only a
single joint and in some cases only a single structure from a single
joint (i.e., hyaline cartilage or meniscus). This fact could explain theTable III
Summary of definitions used in the studies for US diagnosis of CPPD
Structure
assessed
Percentage
of description
Shape of CPP crystals
Fibrocartilage 62% ✓ Spots (“punctuate pattern”)7,22,25,28,30,34,36,39,42,45
✓ Rounded or amorphous-shaped areas9,11,24,28
✓ Rounded foci29,47
✓ Rounded Deposits20,26,27
✓ Punctate dots23
Hyaline
cartilage
84% ✓ Images parallel to the surfaces, classified as
punctiform or linear if longer4,29
✓ Linear deposits20,24,26,27,46e48
✓ Thin bands parallel to the surfaces of the
hyaline cartilage5,7,9,11,22,25,28,36,39,45
✓ Spots not generating a posterior acoustic
shadow10,25,38,39,42
✓ “Rosary beads signs” e punctate dots23
✓ Aggregates that could be linear or homogeneous
Tendons 43% ✓ Linear deposits, parallel to the tendon fibrillar
structure, not in continuity with the bone profile
It could be single or multiple6,25,29,30,36,39
✓ Spots e “punctate” pattern7,24,28
✓ Linear and extensive and may generate an
acoustic shadow9,11,37,39,43
Synovial fluid 12% ✓ Spots without acoustic posterior shadowing32,41
✓ Uniformly rounded in shape with a sharply
defined outer profile.9
✓ Aggregates uniformly rounded in shape
with sharply defined margins24differences in diagnostic accuracy, because not all structures are
affected by CPP deposition at the same time and with the same
extension36.
In fact, the sensitivity of US in detecting CPPD varies according
to the structure under examination ranging from 34% (tendon) to
80% (hyaline cartilage). Sensitivity and specificity compared toEchogenicity of CPP crystals Localization of CPP crystals
✓ Defined as
Hyperechoic/Hyperechogenic
in all the studies
✓ Characterized by echogenicity
similar to the bone cortex
even at very low levels of gain11
✓ Localized within the fibrocartilage
in all the studies
✓ It could be localized also on the
surface of meniscal fibrocartilage34
37
✓ Defined as
Hyperechoic/Hyperechogenic
in all the studies
✓ Localized within the hyaline
cartilage in all the studies
✓ In could be localized on the
superficial margin of the
hyaline cartilage, resembling
the double contour sign typical
of UA deposits20
.
✓ Defined as
Hyperechoic/Hyperechogenic
in all the studies
✓ Localized within the tendons
in all the studies
✓ Defined as
Hyperechoic/Hyperechogenic
in all the studies
✓ Localized within the synovial
fluid in all the studies
Fig. 4. Characteristic US images of CPPD appearance. Even if these patterns are frequently observed, they are not exclusive of the appearance of CPPD and other forms and shapes of
deposits may be encountered. CPPD appears as hyperechoic deposits with echogenicity similar to that of the bone profile. A: hyperechoic deposits within the hyaline cartilage layer
of the knee B: hyperechoic deposits within Achilles tendon. C: hyperechoic deposits within synovial fluid (only two of them indicated in this illustration). D: hyperechoic deposits
within meniscal fibrocartilage. Legend: arrowheads: CPP deposition, curved arrows: the bone profile, arrows: tendon margins, HC: hyaline cartilage layer (anechoic/hypoechoic on
US), SF (anechoic/hypoechoic on US), grey line in frame D individuates the lateral meniscus of the knee.
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981 979synovial fluid analysis were high, suggesting that US may help also
in the diagnosis of CPPD and not only of CC. The low sensitivity at
the tendon level is probably due to a late involvement of this
structure in the natural history of CPPD36. On the other hand,
specificity is high, independently of the examined structure (range
from 93% to 100%). This indicates that the US appearance of CPP
deposition is quite characteristic and well defined in the literature.
Finally, if we consider the values of sensitivity and specificity at the
patient level (all structures of several examined joints) sensitivity is
91% and specificity 97%. Thus, the best values of diagnostic accuracy
are obtained if we consider both fibrocartilage and hyaline carti-
lage, preferably in more than one joint.
Further, the sensitivity and specificity values of the studies
varied also depending on the gold standard used for diagnosis. Ten
studies used the presence of CPP crystals in the synovial fluid (SF)
alone as the criterion for the diagnosis. Only few studies used the
McCarty's criteria (SF þ radiological positivity) and even less
studies used radiography or histology alone as criterion for the
diagnosis (see Table I). There are different interpretations for these
data. First, there is no evidence on sensitivity and specificity of SF
analysis for diagnosis of CPPD, because it has never been tested
against another gold standard. Only recently35, the sensitivity of SF
analysis (70%) and its role as diagnostic gold standard have been
challenged. On the other hand, the use of a strict gold standard,
such as histology of the cartilage and fibrocartilage, produced lower
values of sensitivity and specificity probably because the presence
of crystals in the joint is not detectable by US before the aggregates
reach sufficient dimensions.
Of all studies included in the review, only four10,36,41,43 assessed
the inter-observer agreement, while no study evaluated the intra-
observer agreement. In two of these studies10,41 the agreement
has been assessed only at the hyaline cartilage level and in the other
two36,43 both at the level of hyaline cartilage andof thefibrocartilage
of the knee. In two studies, assessment was compared between
expert and a non-expert operators10,41whereas in three studies only
experts were involved. Therefore, the results are variable and not
easily comparable, with differences in agreement between menisci
and hyaline cartilage. Values of kappa ranged from 0.55 to 0.81 for
the hyaline cartilage and from 0.68 to 1 for the menisci.
The criteria for US identification of CPP deposition in fibro-
cartilage and hyaline cartilage were quite similar in all the studies
and consisted in the presence of hyperechoic deposits (ovalar orround shaped spots) in the context of hyaline cartilage and fibro-
cartilage. Diagnostic accuracy and reliability of US in these struc-
tures were high in all studies, indicating that the US appearance of
CPPD in these structures is acceptably defined and understood by
sonographers. CPPD affecting the tendons is usually described as
linear hyperechoic deposition that is disposed along their long axis.
The diagnostic accuracy of US by evaluating tendons is rather low
regarding sensitivity and this could be due to the definitions or to
the late involvement of tendons in the disease course36. The
deposition of CPP on the superficial margin of the hyaline carti-
lage20,25, mimicking the double contour sign of uric acid deposition,
has been described. Since this is considered the most specific sign
of gout49, the finding should be further investigated in order to
avoid misdiagnosis.
Finally, the overall quality of the studies included in the review
was acceptable and the risk of bias was low. The number of studies
was small and most of them used similar US techniques and defi-
nitions for CPPD, and evaluated similar joints (mainly the knee)
thusmaking most of the studies of diagnostic accuracy comparable.
The potential confounders and reasons for false positive and
negative results, and some tricks that could facilitate CPPD identi-
fication by US were also described9,10,20,25,33. Another issue that
could be raised regarding the US CPPD deposition is the nature of
the hyperechoic deposits. One study aimed to assess the validity of
the method by demonstrating that hyperechoic deposits in the
menisci are real CPP deposits at microscopic analysis34. However,
this study does not exclude that hyperechoic deposits found in
other sites, different that fibrocartilage, could be of different nature
but on the other hand there has not been any evidence until now,
demonstrating that the US CPP deposits are due to other calcium
crystals. A common limitation of most of the studies is the small
number of patients included and in some the different comparator
used (healthy controls or patients affected by other rheumatic
diseases). Such methodological heterogeneity also accounts for the
small study effect.
Therefore, according to the data available in the literature, US
seems to be a promising tool for the diagnosis of CPPD but there are
some aspects that have to be further assessed. The future research
agenda should include the creation of universally accepted and
reliable definitions for US identification of CPPD in all anatomical
structures, the assessment of the reliability and the evaluation of
sensitivity and specificity of the new criteria against a reliable gold
G. Filippou et al. / Osteoarthritis and Cartilage 24 (2016) 973e981980standard. However, even with some gaps in the actual knowledge,
US has demonstrated to be, in trained hands, a valuable tool as it
allows the evaluation of more joints in fewminutes, the assessment
of inflammation or other joint pathologies and the identification of
CPPD deposits. Therefore, we believe that US, thanks also to its
intrinsic characteristics, could be the first line exam when CPPD is
suspected while SF analysis could be used for difficult cases or for
all these cases when arthrocentesis is also indicated for therapeutic
reasons. The role of CR has to be further established as the actual
data do not indicate a clear advantage of CR over the other two
methods. Finally, it is not clear if the combination of two or more
techniques could further improve the diagnostic accuracy for CPPD,
and this aspect should be further evaluated.
In conclusion, the data emerged from this meta-analysis indi-
cate that US could be a useful tool in the diagnosis of CPPD but
further studies are necessary to address its effective potential. The
different clinical subsets of CPPD complicate the evaluation of the
usefulness of US. All studies included in this meta-analysis
addressed the first problem. Further, it is necessary to find a
feasible and reliable gold standard for CPPD diagnosis vs whom all
diagnostics methods should be tested. A new set of accepted US
diagnostic criteria, could help to further improve the accuracy of
the exam, mainly in the sites where US has a low potential (i.e.,
tendons). Finally, the reliability of the method, in particular intra-
and inter-observer agreement should be studied. Then, the clinical
utility and feasibility of USwill be fully addressed and the technique
could become an important tool in the diagnosis of CPPD.
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